About Can-Fite BioPharma (NYSEAMERICAN:CANF)
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-57.94%
Return on Assets-32.52%
Frequently Asked Questions for Can-Fite BioPharma (NYSEAMERICAN:CANF)
What is Can-Fite BioPharma's stock symbol?
Can-Fite BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."
How were Can-Fite BioPharma's earnings last quarter?
Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) announced its quarterly earnings results on Tuesday, May, 31st. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. Can-Fite BioPharma had a negative net margin of 2,453.03% and a negative return on equity of 57.94%. View Can-Fite BioPharma's Earnings History.
When will Can-Fite BioPharma make its next earnings announcement?
Where is Can-Fite BioPharma's stock going? Where will Can-Fite BioPharma's stock price be in 2017?
2 brokerages have issued 12-month target prices for Can-Fite BioPharma's shares. Their predictions range from $6.00 to $7.00. On average, they expect Can-Fite BioPharma's stock price to reach $6.50 in the next twelve months. View Analyst Ratings for Can-Fite BioPharma.
Who are some of Can-Fite BioPharma's key competitors?
Some companies that are related to Can-Fite BioPharma include OncoSec Medical Incorporated (ONCS), Ohr Pharmaceuticals (OHRP), Prima BioMed Ltd (PBMD), AEterna Zentaris (AEZS), Bio-Path Holdings (BPTH), Scancell Holdings Plc (SCLP), Oncobiologics (ONS), Genocea Biosciences (GNCA), Caladrius Biosciences (CLBS), Prana Biotechnology Ltd (PRAN), Cleveland BioLabs (CBLI), Fibrocell Science (FCSC), OncoGenex Pharmaceuticals (ACHV), Repros Therapeutics (RPRX), Burcon NutraScience Corp (BUR), RXi Pharmaceuticals Corporation (RXII), Synairgen plc (SNG) and Oxford Pharmascience Group Plc (OXP).
Who are Can-Fite BioPharma's key executives?
Can-Fite BioPharma's management team includes the folowing people:
- Ilan Cohen, Chairman of the Board (Age 61)
- Pnina Fishman Ph.D., Chief Executive Officer, Director (Age 67)
- Motti Farbstein, Chief Financial Officer, Chief Operating Officer (Age 51)
- Guy Regev, Director (Age 47)
- Abraham Sartani M.D., Director (Age 68)
- Israel Shamay, External Director (Age 51)
How do I buy Can-Fite BioPharma stock?
Shares of Can-Fite BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Can-Fite BioPharma's stock price today?
One share of Can-Fite BioPharma stock can currently be purchased for approximately $1.43.
How big of a company is Can-Fite BioPharma?
Can-Fite BioPharma has a market capitalization of $24.54 million. Can-Fite BioPharma employs 7 workers across the globe.
How can I contact Can-Fite BioPharma?
Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company can be reached via phone at +972-3-9241114.
MarketBeat Community Rating for Can-Fite BioPharma (CANF)MarketBeat's community ratings are surveys of what our community members think about Can-Fite BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Can-Fite BioPharma (NYSEAMERICAN:CANF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$6.50|
Consensus Price Target History for Can-Fite BioPharma (NYSEAMERICAN:CANF)
Analysts' Ratings History for Can-Fite BioPharma (NYSEAMERICAN:CANF)
(Data available from 11/23/2015 forward)
|10/31/2017||HC Wainwright||Reiterated Rating||Buy|
|10/30/2017||Maxim Group||Set Price Target||Buy||$7.00|
|10/18/2016||Roth Capital||Reiterated Rating||Buy|
|8/29/2016||Rodman & Renshaw||Initiated Coverage||Buy||$6.00|
Earnings History and Estimates Chart for Can-Fite BioPharma (NYSEAMERICAN:CANF)
Earnings History by Quarter for Can-Fite BioPharma (NYSEAMERICAN CANF)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/24/2017|| || || || || || || || |
Earnings Estimates for Can-Fite BioPharma (NYSEAMERICAN:CANF)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Can-Fite BioPharma (NYSEAMERICAN:CANF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Can-Fite BioPharma (NYSEAMERICAN CANF)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Can-Fite BioPharma (NYSEAMERICAN CANF)
Financials are not available for this stock.
Can-Fite BioPharma (NYSEAMERICAN CANF) Chart for Thursday, November, 23, 2017